The Experts below are selected from a list of 6192 Experts worldwide ranked by ideXlab platform
Hiroshi Tomita - One of the best experts on this subject based on the ideXlab platform.
-
Double-blind, placebo-controlled trial of zinc Picolinate for taste disorders.
Acta oto-laryngologica. Supplementum, 2002Co-Authors: Fumitaka Sakai, Shinya Yoshida, Sohei Endo, Hiroshi TomitaAbstract:A total of 73 patients with an idiopathic zinc-deficiency taste disorder completed a double-blind, placebo-controlled trial of the efficacy of zinc Picolinate. Patients in the zinc treatment group (n = 37) received 29 mg of zinc Picolinate orally by capsule 3 times a day for 3 months. No significant difference was noted between the treatment and placebo groups in terms of improvement in subjective symptoms or whole-mouth taste sensation. However, assessment of taste using the filter paper disk method showed significantly better improvement for the group given zinc, and the serum zinc level was also significantly higher in this group than in the placebo control group.
-
THERAPEUTIC EFFICACY OF ZINC Picolinate IN PATIENTS WITH TASTE DISORDERS
Nippon Jibiinkoka Gakkai Kaiho, 1995Co-Authors: Fumitaka Sakai, Shinya Yoshida, Sohei Endo, Hiroshi TomitaAbstract:We studied the therapeutic efficacy of zinc Picolinate in patients with zinc-deficient and idiopathic taste disorders. Efficacy was assessed in a double-blind study. The following findings were obtained:1. There was a significant difference between the zinc Picolinate and placebo groups in the grade of improvement shown by the filter-paper disk method.2. There was a significant difference between the zinc Picolinate and placebo groups in the serum zinc concentration.3. There was no significant difference between the two groups in the degree of total subjective recovery or the grade of improvement, as shown by in the whole mouth method.4. We conclude that the administration of zinc Picolinate is effective for patients with zincdeficient and idiopathic taste disorders.
-
Clinical Experience of Zinc Picolinate in the Treatment of Patients with Taste Disorders
Olfaction and Taste XI, 1994Co-Authors: Yoichiro Yamada, Sohei Endo, Koichi Ishiyama, Ken-ichi Watanabe, Hiroshi TomitaAbstract:The clinical efficacy of zinc Picolinate in the treatment of taste disorders was assessed in an open trial.
Joseph A Caruso - One of the best experts on this subject based on the ideXlab platform.
-
elemental speciation for chromium in chromium Picolinate products
Spectrochimica Acta Part B: Atomic Spectroscopy, 1996Co-Authors: Hong Ding, Lisa K Olson, Joseph A CarusoAbstract:Chromium Picolinate products have been examined for different forms of chromium, using chromatographic separation and inductively coupled plasma mass spectrometric detection. The brands we evaluated contained no detectable amount of elemental chromium(VI), the toxic form. Since chromium Picolinate might have other chromium forms as impurities, different products may contain different forms of chromium species. Compared with ion-exchange, reversed-phase chromatography showed excellent chromium recovery based on the amount stated on the product label.
Nunes, Marília Porto Oliveira - One of the best experts on this subject based on the ideXlab platform.
-
Relação da suplementação de picolinato de cromo com a perda de peso em mulheres
IBPEFEX, 2019Co-Authors: Nobre, Charliane Benvindo, Nepomuceno, Ariane Saraiva, Nunes Filho, Júlio César Chaves, De Matos, Robson Salviano, Nunes, Marília Porto OliveiraAbstract:In the intention of reducing weight in obese, some strategies related to physical activity and use of bioactive have been used. Objective: To relate the weight loss of women practicing resistance training with the use of chromium Picolinate. This was a randomized, placebo-controlled trial involving 30 women, with a BMI above 25Kg m 2 and regular resistance training practitioners. The participants were divided in two groups, being G1 (experimental) and G2 (control), in a random way to receive the supplementation for 30 days. All participants were submitted to the same training protocol, which was elaborated and accompanied by a physical educator. One day before and one day after the supplementation period, anthropometric assessments were performed and the food recall was verified. For statistical analysis, the Mann Whitney and t paired tests were used for intragroup and Wilcoxon comparisons, and t was independent for intergroup comparisons. When comparing intragroups, pre and post intervention, a significant statistical difference in body weight, BMI, CC, CQ and% G (p <0.001) was observed in G1. Group G2, only fat percentage presented statistical difference (p <0.000). When comparing intergroups, pre and post intervention, no statistical difference (p> 0.05) was observed in any variable. Through this study it can be concluded that the use of 30-day supplementation of 400mcg of chromium Picolinate does not contribute to the reduction of body fat in overweight obese women practicing resistance training.Na intenção da redução de peso em obesos, algumas estratégias relacionadas a atividade física e uso de bioativos vem sendo utilizadas. Objetivo: Relacionar a perda de peso de mulheres praticantes de treinamento resistido com o uso do picolinato de cromo. Tratou-se de um ensaio clínico randomizado e controlado por placebo envolvendo 30 mulheres, com IMC acima de 25Kgm² e praticantes regulares de treinamento de resistência. As participantes foram divididas em dois grupos, sendo G1 (experimental) e G2 (controle), de forma aleatória para recebimento da suplementação por 30 dias. Todas as participantes foram submetidas ao mesmo protocolo de treino, o qual foi elaborado e acompanhado por um educador físico. Um dia antes e um dia após o período da suplementação foram realizadas avaliações antropométricas e verificado o recordatório alimentar. Para análise estatística, foram utilizados os testes Mann Whitney e t pareado para comparação intragrupos e Wilcoxon e t indepedente para comparação intergrupos. Quando feita a comparação intragrupos, pré e pós intervenção, foi observado, no G1, uma diferença estatística significativa no peso corporal, IMC, CC, CQ e %G (p<0,001). O grupo G2, apenas o percentual de gordura apresentou diferença estatística (p<0,000). Quando comparado intergrupos, pré e pós intervenção, não foi observada diferença estatística (p>0,05) em nenhuma variável. Através deste estudo pode-se concluir que o uso da suplementação por 30 dias de 400mcg de picolinato de cromo, não contribui para a redução da gordura corporal em mulheres com sobrepeso obesidade praticantes de treinamento de resistência. ABSTRACT Relationship of chromium Picolinate supplementation with weight loss in womenIn the intention of reducing weight in obese, some strategies related to physical activity and use of bioactive have been used. Objective: To relate the weight loss of women practicing resistance training with the use of chromium Picolinate. This was a randomized, placebo-controlled trial involving 30 women, with a BMI above 25Kg m 2 and regular resistance training practitioners. The participants were divided in two groups, being G1 (experimental) and G2 (control), in a random way to receive the supplementation for 30 days. All participants were submitted to the same training protocol, which was elaborated and accompanied by a physical educator. One day before and one day after the supplementation period, anthropometric assessments were performed and the food recall was verified. For statistical analysis, the Mann Whitney and t paired tests were used for intragroup and Wilcoxon comparisons, and t was independent for intergroup comparisons. When comparing intragroups, pre and post intervention, a significant statistical difference in body weight, BMI, CC, CQ and% G (p <0.001) was observed in G1. Group G2, only fat percentage presented statistical difference (p <0.000). When comparing intergroups, pre and post intervention, no statistical difference (p> 0.05) was observed in any variable. Through this study it can be concluded that the use of 30-day supplementation of 400mcg of chromium Picolinate does not contribute to the reduction of body fat in overweight obese women practicing resistance training
-
Relação da suplementação de picolinato de cromo com a perda de peso em mulheres
2019Co-Authors: Nobre, Charliane Benvindo, Nepomuceno, Ariane Saraiva, Nunes Filho, Júlio César Chaves, De Matos, Robson Salviano, Nunes, Marília Porto OliveiraAbstract:In the intention of reducing weight in obese, some strategies related to physical activity and use of bioactive have been used. Objective: To relate the weight loss of women practicing resistance training with the use of chromium Picolinate. This was a randomized, placebo-controlled trial involving 30 women, with a BMI above 25Kg m 2 and regular resistance training practitioners. The participants were divided in two groups, being G1 (experimental) and G2 (control), in a random way to receive the supplementation for 30 days. All participants were submitted to the same training protocol, which was elaborated and accompanied by a physical educator. One day before and one day after the supplementation period, anthropometric assessments were performed and the food recall was verified. For statistical analysis, the Mann Whitney and t paired tests were used for intragroup and Wilcoxon comparisons, and t was independent for intergroup comparisons. When comparing intragroups, pre and post intervention, a significant statistical difference in body weight, BMI, CC, CQ and% G (p 0.05) was observed in any variable. Through this study it can be concluded that the use of 30-day supplementation of 400mcg of chromium Picolinate does not contribute to the reduction of body fat in overweight obese women practicing resistance training.Na intenção da redução de peso em obesos, algumas estratégias relacionadas a atividade física e uso de bioativos vem sendo utilizadas. Objetivo: Relacionar a perda de peso de mulheres praticantes de treinamento resistido com o uso do picolinato de cromo. Tratou-se de um ensaio clínico randomizado e controlado por placebo envolvendo 30 mulheres, com IMC acima de 25Kgm² e praticantes regulares de treinamento de resistência. As participantes foram divididas em dois grupos, sendo G1 (experimental) e G2 (controle), de forma aleatória para recebimento da suplementação por 30 dias. Todas as participantes foram submetidas ao mesmo protocolo de treino, o qual foi elaborado e acompanhado por um educador físico. Um dia antes e um dia após o período da suplementação foram realizadas avaliações antropométricas e verificado o recordatório alimentar. Para análise estatística, foram utilizados os testes Mann Whitney e t pareado para comparação intragrupos e Wilcoxon e t indepedente para comparação intergrupos. Quando feita a comparação intragrupos, pré e pós intervenção, foi observado, no G1, uma diferença estatística significativa no peso corporal, IMC, CC, CQ e %G (p0,05) em nenhuma variável. Através deste estudo pode-se concluir que o uso da suplementação por 30 dias de 400mcg de picolinato de cromo, não contribui para a redução da gordura corporal em mulheres com sobrepeso obesidade praticantes de treinamento de resistência. ABSTRACT Relationship of chromium Picolinate supplementation with weight loss in womenIn the intention of reducing weight in obese, some strategies related to physical activity and use of bioactive have been used. Objective: To relate the weight loss of women practicing resistance training with the use of chromium Picolinate. This was a randomized, placebo-controlled trial involving 30 women, with a BMI above 25Kg m 2 and regular resistance training practitioners. The participants were divided in two groups, being G1 (experimental) and G2 (control), in a random way to receive the supplementation for 30 days. All participants were submitted to the same training protocol, which was elaborated and accompanied by a physical educator. One day before and one day after the supplementation period, anthropometric assessments were performed and the food recall was verified. For statistical analysis, the Mann Whitney and t paired tests were used for intragroup and Wilcoxon comparisons, and t was independent for intergroup comparisons. When comparing intragroups, pre and post intervention, a significant statistical difference in body weight, BMI, CC, CQ and% G (p 0.05) was observed in any variable. Through this study it can be concluded that the use of 30-day supplementation of 400mcg of chromium Picolinate does not contribute to the reduction of body fat in overweight obese women practicing resistance training
Chaitali Biswas - One of the best experts on this subject based on the ideXlab platform.
-
anion π lone pair π π π and hydrogen bonding interactions in a cuii complex of 2 Picolinate and protonated 4 4 bipyridine crystal structure and theoretical studies
European Journal of Inorganic Chemistry, 2009Co-Authors: Chaitali Biswas, Michael G B Drew, Daniel Escudero, Antonio Frontera, Ashutosh GhoshAbstract:AC u II complex of protonated 4,4-bipyridine (Hbyp) and 2Picolinate (pic), [Cu2(pic)3(Hbyp)(H2O)(ClO4)2], has been synthesised and characterised by single-crystal X-ray analysis. The structure consists of two copper atoms that have different environments, bridged by a carboxylate group. The equatorial plane is formed by the two bidentate Picolinate groups in one CuII , and one Picolinate, one monodentate 4,4-bipyridyl ligand and a water molecule in the other. Each copper atom is also weakly bonded to a perchlorate anion in an axial position. One of the coordinated perchlorate groups displays anion–π interaction with the coordinated pyridine ring. The noncoordinated carboxylate oxygen is involved in lone-pair (l.p.)–π interaction with the protonated pyridine ring. In addition there are π–π and H-bonding interactions in the structure. Bader’s theory of “atoms in molecules” (AIM)
Kathleen C Ellwood - One of the best experts on this subject based on the ideXlab platform.
-
chromium Picolinate intake and risk of type 2 diabetes an evidence based review by the united states food and drug administration
Nutrition Reviews, 2006Co-Authors: Paula R Trumbo, Kathleen C EllwoodAbstract:The labeling of both health claims that meet significant scientific agreement (SSA) and qualified health claims on conventional foods and dietary supplements requires pre-market approval by the US Food and Drug Administration (FDA). Approval by the FDA involves, in part, a thorough review of the scientific evidence to support an SSA or a qualified health claim. This article discusses FDA's evidence-based review of the scientific evidence on the role of chromium Picolinate supplements in reducing the risk of type 2 diabetes. Based on this evidence-based review, FDA issued a letter of enforcement discretion for one qualified health claim on chromium Picolinate and risk of insulin resistance, a surrogate endpoint for type 2 diabetes. The agency concluded that the relationship between chromium Picolinate intake and insulin resistance is highly uncertain.
